[1] |
SIEGEL R L,, MILLER K D,, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021,71(1):7-33.
|
[2] |
HEDGIRE S,, KILCOYNE A,, TONYUSHKIN A, et al. Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: can we assess treatment response on imaging?[J]. Br J Radiol, 2019,92(1093):20170170.
|
[3] |
COAKLEY F V,, TEH H S,, QAYYUM A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience[J]. Radiology, 2004,233(2):441-448.
|
[4] |
HOFMAN M S,, LAWRENTSCHUK N,, FRANCIS R J, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]. Lancet, 2020,395(10231):1208-1216.
|
[5] |
FENDLER W P,, FERDINANDUS J,, CZERNIN J, et al. Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial [J]. J Nucl Med, 2020,61(12):1793-1799.
|
[6] |
AFSHAR-OROMIEH A,, HABERKORN U,, SCHLEMMER H P, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience [J]. Eur J Nucl Med Mol Imaging, 2014,41(5):887-897.
|
[7] |
EIBER M,, MAURER T,, SOUVATZOGLOU M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy [J]. J Nucl Med, 2015,56(5):668-674.
|
[8] |
MORIGI J J,, STRICKER P D,, VAN LEEUWEN P J, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy [J]. J Nucl Med, 2015,56(8):1185-1190.
|
[9] |
LAWAL I O,, ANKRAH A O,, MOKGORO N P, et al. Diagnostic sensitivity of Tc- 99m hynic PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT [J]. Prostate, 2017,77(11):1205-1212.
|
[10] |
ONAL C,, GULER O C,, TORUN N, et al. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients [J]. Eur J Nucl Med Mol Imaging, 2020,47(3):632-641.
|
[11] |
PANEBIANCO V,, VILLEIRS G,, WEINREB J C, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy[J]. Eur Urol Oncol, 2021,4(6):868-876.
|
[12] |
胡四龙,, 许晓平,, 朱耀, 等. 99mTc标记PSMA小分子抑制剂靶向前列腺癌分子影像初步临床研究 [J]. 中国癌症杂志, 2016,26(7):608-615.
|
|
HU S L,, XU X P,, ZHU Y, et al. Preliminary clinical study of 99mTc-labelled small molecules against PSMA for prostate cancer imaging [J]. China Oncol, 2016,26(7):608-615.
|
[13] |
许晓平,, 张建平,, 何思敏, 等. 前列腺特异性膜抗原小分子抑制剂显像研究[J]. 肿瘤影像学, 2015,24(3):173-178.
|
|
XU X P,, ZHANG J P,, HE S M, et al. The imaging study of a small-molecular inhibitor targeting prostate specific membrane antigen[J]. Oncoradiology, 2015,24(3):173-178.
|
[14] |
MCKAY R R,, MONTGOMERY B,, XIE W L, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade[J]. Prostate Cancer Prostatic Dis, 2018,21(3):364-372.
|
[15] |
PETRAKI C D,, SFIKAS C P. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma[J]. Histol Histopathol, 2007,22(1):107-118.
|
[16] |
STABILE A,, GIGANTI F,, ROSENKRANTZ A B, et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions[J]. Nat Rev Urol, 2020,17(1):41-61.
|
[17] |
KATELARIS N C,, BOLTON D M,, WEERAKOON M, et al. Current role of multiparametric magnetic resonance imaging in the management of prostate cancer[J]. Korean J Urol, 2015,56(5):337-345.
|
[18] |
PADHANI A R,, MACVICAR A D,, GAPINSKI C J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging[J]. Radiology, 2001,218(2):365-374.
|
[19] |
MURPHY W M,, SOLOWAY M S,, BARROWS G H. Pathologic changes associated with androgen deprivation therapy for prostate cancer[J]. Cancer, 1991,68(4):821-828.
|
[20] |
JOSEPH I B,, NELSON J B,, DENMEADE S R, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue[J]. Clin Cancer Res, 1997,3(12 Pt 1):2507-2511.
|
[21] |
BARRETT T,, GILL A B,, KATAOKA M Y, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study[J]. Magn Reson Med, 2012,67(3):778-785.
|
[22] |
RØE K,, SEIERSTAD T,, KRISTIAN A, et al. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions[J]. Neoplasia, 2010,12(10):818-825.
|
[23] |
RØE K,, KAKAR M,, SEIERSTAD T, et al. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study[J]. Radiat Oncol, 2011,6:65.
|
[24] |
CHRISTIE D R,, SHARPLEY C F,, MITINA N, et al. Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?[J]. J Med Imaging Radiat Oncol, 2020,64(2):287-292.
|
[25] |
胡四龙,, 许晓平,, 朱耀, 等. 99mTc-PSMA SPECT/CT探测前列腺癌病灶的临床应用价值 [J]. 肿瘤影像学, 2016,25(3):272-278.
|
|
HU S L,, XU X P,, ZHU Y, et al. Clinical value of 99mTc-PSMA SPECT/CT in detection of prostate cancer [J]. Oncoradiology, 2016,25(3):272-278.
|
[26] |
REINFELDER J,, KUWERT T,, BECK M, et al. First experience with SPECT/CT using a 99mTc-labeled inhibitor for prostate-specific membrane antigen in patients with biochemical recurrence of prostate cancer [J]. Clin Nucl Med, 2017,42(1):26-33.
|
[27] |
GARCÍA-PÉREZ F O,, DAVANZO J,, LÓPEZ-BUENROSTRO S, et al. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients [J]. Am J Nucl Med Mol Imaging, 2018,8(5):332-340.
|
[28] |
KWAK C,, JEONG S J,, PARK M S, et al. Prognostic significance of the nadir prostate-specific antigen level after hormone therapy for prostate cancer[J]. J Urol, 2002,168(3):995-1000.
|
[29] |
EVANS M J,, SMITH-JONES P M,, WONGVIPAT J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen[J]. Proc Natl Acad Sci USA, 2011,108(23):9578-9582.
|
[30] |
VAZ S,, HADASCHIK B,, GABRIEL M, et al. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2020,47(1):9-15.
|